Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
Point’s big Splash falls short
Crossover hits overall survival, pouring doubts on the group’s deal hopes.
SABCS 2023 – SERDs square off in combinations
Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?
Roche seeks alpha to defeat Novartis
With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.
Investors brush off Car-T scare
But the FDA’s investigation looks like worse news for autoimmune disease than oncology.
A curate’s egg for MorphoSys
Pelabresib’s Manifest-2 trial yields mixed data, but the bad part could render the whole unpalatable.
